What's new?

This update contains 73 revised monographs and 9 new monographs.

For a list of the monographs in this update, click here (PDF).

This update contains 7 new monographs and 54 revised monographs, including MedWatch alerts from November.

For a list of the monographs in this update, click here (PDF).

This update contains 1 new monograph and 21 revised monographs, and many with added REMS statements.

For a list of the monographs in this update, click here (PDF).

This update contains 16 revised and 2 new monographs, including MedWatch alerts from September.

For a list of the monographs in this update, click here (PDF).

This update contains 22 revised and 7 new monographs, including MedWatch alerts from July and August.

For a list of the monographs in this update, click here (PDF).

This update contains 15 revised monographs, including MedWatch alerts from May.

For a list of the monographs in this update, click here (PDF).

This update contains 9 revised and 1 new monograph.

For a list of the monographs in this update, click here (PDF).

This update contains 15 revised monographs, including MedWatch alerts from April.

For a list of the monographs in this update, click here (PDF).

This update contains 39 revised monographs, including MedWatch alerts from March.

For a list of the monographs in this update, click here (PDF).

This update contains 35 revised and 6 new monographs, including MedWatch alerts from February. Two monographs have been deleted.

For a list of the monographs in this update, click here (PDF).

This update contains 3 new and 64 revised monographs, including MedWatch alerts from December.

For a list of the monographs in this update, click here (PDF).

This update contains 36 revised monographs and 3 new monographs, including MedWatch alerts from November.

For a list of the monographs in this update, click here (PDF).

This update contains 16 revised and 1 new monograph, including MedWatch alerts from October.

For a list of the monographs in this update, click here (PDF).

This update contains 10 revised and 2 new monographs.

For a list of the monographs in this update, click here (PDF).

This update contains 15 revised and 6 new monographs, including MedWatch alerts from August.

For a list of the monographs in this update, click here (PDF).

This update contains 1 new and 17 revised monographs, including MedWatch alerts from July.

For a list of the monographs in this update, click here (PDF).

This update contains 9 revised monographs and 4 new monographs, including MedWatch alerts from June.

For a list of the monographs in this update, click here (PDF).

This update contains 17 revised monographs, including MedWatch alerts from May.

For a list of the monographs in this update, click here (PDF).

This update contains 6 revised and 1 new monograph, including MedWatch alerts from April.

For a list of the monographs in this update, click here (PDF).

This update contains 14 revised monographs, including MedWatch alerts from March.

For a list of the monographs in this update, click here (PDF).

This update contains 3 new monographs, and MedWatch alerts for over 30 drugs.

For further details, click here (PDF).

This update contains 20 revised monographs.

For a list of the monographs in this update, click here (PDF).

This update contains 4 new and 40 revised monographs, including MedWatch alerts from November.

For a list of the monographs in this update, click here (PDF).

This update contains 23 revised monographs, including MedWatch alerts from October.

For a list of the monographs in this update, click here (PDF).

This update contains 4 new and 30 revised monographs.

For further details and a list of the monographs in this update, click here (PDF).

This update contains 1 new and 22 revised monographs, including MedWatch alerts from August.

For a list of the monographs in this update, click here (PDF).

This update contains 36 revised and 5 new monographs, including MedWatch alerts from July.

For a list of the monographs in this update, click here (PDF).

This update contains 4 new and 20 revised monographs, including MedWatch alerts from June.

For a list of the monographs in this update, click here (PDF).

This update contains 15 revised monographs, including MedWatch alerts from May.

For a list of the monographs in this update, click here (PDF).

This update contains 2 new and 9 revised monographs, including MedWatch alerts from April and updated H1N1 virus treatment recommendations.

For a list of the monographs in this update, click here (PDF).

This update contains 19 revised monographs, including MedWatch alerts from March.

For a list of the monographs in this update, click here (PDF).

This update contains 9 revised monographs, with MedWatch alerts from February.

For a list of the monographs in this update, click here (PDF).

Over 700 monographs were revised for inclusion in the 2009 print edition of AHFS Drug Information. These revisions incorporate new or updated therapeutic guidelines from:

• the American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines on Antithrombotic and Thrombolytic Therapy
• US Department of Health and Human Services (HHS) guidelines for the management of HIV infection in adults and children and guidelines for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission
• multiple guidelines regarding screening and treating pediatric patients for lipid disorders from the National Cholesterol Education Program (NCEP), the American Academy of Pediatrics (AAP), and the American Heart Association (AHA) among others
• recommendations for prevention and treatment of opportunistic infections in HIV-infected individuals approved by Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and the HIV Medicine Association of the Infectious Diseases Society of America (IDSA)
• Centers for Disease Control and Prevention (CDC) for influenza vaccination and management
• the latest (January 2009) US Recommended Immunization Schedules for Children and Adolescents, which was issued by the CDC, AAP, and American Academy of Family Physicians (AAFP), as well as the revised (January 2009) US Recommended Immunization Schedules for Adults that incorporates the recommendations of CDC, AAFP, American College of Physicians (ACP), and ACOG
• US Centers for Disease Control and Prevention (CDC) health information for international travel
• AHA and AAP regarding the need for routine ECG screening in all pediatric patients being considered for or currently receiving stimulant therapy.

Dozens of other monographs were revised based on FDA MedWatch notices.

For a full list of new and revised monographs in this online update, click here (PDF).

Highlights of this update include:

• Nebivolol and Nilotinib were expanded from FirstReleases to Overviews.
• Altretamine and Pegaspargase were expanded from Overviews to a full-length monographs.
• Adefovir was revised based on updated treatment guidelines and labeling.
• The other monographs were revised based on labeling changes and recent MedWatch alerts.

For a full list of new and revised monographs in this update, click here (PDF).

Doripenem and Mometasone were expanded from FirstReleases to Overview monographs. MedWatch alerts were added to 9 monographs (Efalizumab, Epoetin alfa, Atorvastatin, HMG-CoA Reductase Inhibitors GS, Rosuvastatin, Lovastatin, Pravastatin, Simvastatin, and Fluvastatin). 6 monographs were updated to include the 2008-2009 influenza season guidelines (Amantadine, Rimantadine, Zanamivir, Oseltamivir, and Influenza Virus Vaccines [Live and Inactivated]).

For a full list of these monographs, click here (PDF).

This update contains 13 revised and 2 new monographs. For full details, click here (PDF).

This update contains 11 revised and 1 new monograph. For full details, click here (PDF).

This update contains 17 revised monographs. For full details, click here (PDF).

This update contains 7 revised monographs and 1 new monograph. A MedWatch notice was added to varenicline, aprotinin, and mycophenolate.

Full details (PDF).

This update contains 10 revised monographs. The monographs for maraviroc and etravirine were expanded from firstReleases to an Overviews and a MedWatch notice was added to etanercept.

Full details (PDF).

This update contains 15 revised monographs and one new monograph. Two monographs were revised due to FDA MedWatch notices. The monograph for raltegravir was expanded from a firstRelease to an Overview.

Full details (PDF).

This update, corresponding to the 2008 print edition, has been updated extensively, and includes MedWatch notices that were issued in January/February 2008.

Full details (PDF).

This update contains 61 revised monographs. The monographs for telbivudine, lapatinib, and paliperidone were expanded from firstReleases to Overviews.

Full details (PDF).

Full details (PDF).

• Temsirolimus
• Levocetirizine
• Eculizumab

• Risedronate
• Zoledronic Acid
• Clopidogrel
• Pergolide
• Ibritumomab
• Budesonide
• Ibandronate
• Posaconazole
• Azathioprine
• Haloperidol
• Trimipramine
• Desipramine
• Imipramine
• Fentanyl
• Pyrethrins with Piperonyl Butoxide (Topical)
• Etidronate
• Ceftriaxone
• Terconazole (Topical)
• Pamidronate
• Valacyclovir
• Alendronate

This update contains 5 new monographs and 19 revisions. Anidulafungin was upgraded from a FirstRelease monograph to an Overview monograph.

This update contains 8 revised monographs. It also contains 2 new monographs: aliskirin hemifumarate and lisdexamfetamine dimesylate. Aliskirin has been preliminarily assigned to class 24:32. However, a new sub-classification 24:32.40 - "Renin Inhibitors" - will be created, and this drug will be moved to the new class in due course.

This update contains 17 revised monographs. It also includes 1 monograph (sorafenib) that was upgraded from a firstRelease to an Overview.

This update contains 9 revised monographs: docosanol (topical), tizanidine, telithromycin, rotavirus vaccine live oral, acetaminophen, estrogen-progestin combinations, trimethobenzamide, norfloxacin, ofloxacin.

Of these, 3 monographs were revised due to Medwatch notices from the FDA (telithromycin, tizanidine, trimethobenzamide, and rotavirus vaccine).

This update contains 2 new monographs and 39 revised monographs. A total of 21 monographs were revised due to Medwatch notices from the FDA (atomoxetine, cyclosporine, darbepoetin, dexmethylphenidate, dextroamphetamine, entecavir, epoetin alfa, eszopiclone, interferon gamma, linezolid, methylphenidate, mycophenolate, omalizumab, pioglitazone, ramelteon, rosiglitazone, tacrolimus, temazepam, triazolam, zaleplon, zolpidem). In addition, the new monograph, Sitagliptin, has been added to a new therapeutic class: "68:20.05 - Dipeptidyl Peptidase-4 (DPP-4) Inhibitors".

Seven new monographs have been added to the database, reflecting recent new drug approvals by the FDA:

• Omega-3-acid Ethyl Esters, approved as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with TG levels >/= 500 mg/dL
• Abatacept, approved for reducing the signs and symptoms of rheumatoid arthritis (RA), inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate (MTX) or tumor necrosis factor (TNF) antagonists
• Mecasermin, approved for long-term treatment of a rare type of hormone deficiency that causes children to be much shorter than their peers and to grow at a much slower rate; a human insulin-like growth factor-1 (IGF-1) produced by recombinant DNA technology
• Lenalidomide, approved for myelodysplastic syndrome (but a supplemental new drug application (sNDA) has already been filed for relapsed or refractory multiple myeloma)
• Sorafenib, approved for advanced renal cell carcinoma (RCC)
• Lubiprostone, approved for chronic idiopathic constipation
• Insulin Glulisine, a human insulin analog that is a rapid-acting, parenteral blood glucose lowering agent

The following monographs have been updated to include new precautionary information issued by the FDA (MedWatch Notices): Gatifloxacin, Telithromycin, Aprotinin, Nimodipine, Clozapine, Benzocaine, Pimecrolimus, Denileukin, Bosentan, Mifepristone, Paroxetine, Rosiglitazone, and Immune Globulin.

In addition, 156 other monographs have been revised, including updated product listings.

The coverage of the 2006 edition has been expanded to include 31 new drug monographs:

• Increased granularity of the AHFS Classification and CMS Medicare Part D recognition
• Extensively revised product listings
• Current authoritative therapeutic guidelines updated
• Major cautionary information revised

The American Hospital Formulary Service (AHFS)is now available on MedicinesComplete.

For further information, please see (PDF).

Users wishing to subscribe to AHFS may do so by contacting their regional sales team as detailed below:

UK & ROW

Pharmaceutical Press

1 Lambeth High Street

London

SE1 7JN

Tel: +44 (0)20 7572 2464

Email: sales@medicinescomplete.com

The Americas

Pharmaceutical Press

1537 St. Paul Avenue

Gurnee Illinois 60031

Tel: +1 877 471 4747

Email: sales_americas@pharmpress.com

Or select 'Subscribe' on the MedicinesComplete homepage